A Phase 1 interventional study of BMS-986446 in Alzheimer's Disease and Healthy Participants, sponsored by Bristol-Myers Squibb. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Alzheimer Disease by Bristol-Myers Squibb — 12 open to participants now, 13 under way, 10 of them phase 3. Alzheimer Disease · Bristol-Myers Squibb.
Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 26th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →12 of the 26 studies in Alzheimer Disease by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 2 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 23 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 14 more countries
Ages 60–85
Bristol-Myers Squibb · Sites in United States, Argentina, Chile and 11 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 16 more countries
Ages 60–85
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 165 across the 26 interventional studies. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
6 of the studies in Alzheimer Disease by Bristol-Myers Squibb that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT07780383Bristol-Myers SquibbA Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration | 2027-06-17 |
Add all 6 to your calendar (.ics) → With an account.
Among the 26 studies in Alzheimer Disease by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986446
Drug: BMS-986446
Drug: BMS-986446
Drug: BMS-986446
Drug: BMS-986446
Drug: BMS-986446
Specified dose on specified days
Also known as: PRX005, Moponetug
Absolute bioavailability estimated from geometric mean ratio (GMR) of area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986446 after subcutaneous (SC) infusion
Time frame: Up to approximately 5 months
Absolute bioavailability estimated from GMR of AUC(INF) of BMS-986446 after intravenous (IV) infusion
Time frame: Up to approximately 5 months
Maximum observed concentration (Cmax)
Time frame: Up to approximately 5 months
Time of maximum observed concentration (Tmax)
Time frame: Up to approximately 5 months
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))
Time frame: Up to approximately 5 months
Area under the serum concentration-time curve from time zero to 672 hours (AUC(0-672))
Time frame: Up to approximately 5 months
AUC(INF)
Time frame: Up to approximately 5 months
Half-life (T-HALF)
Time frame: Up to approximately 5 months
Apparent total body clearance in SC administration (CLT/F)
Time frame: Up to approximately 5 months
Total body clearance in IV infusion (CLT)
Time frame: Up to approximately 5 months
Apparent volume of distribution of terminal phase in SC administration (Vz/F)
Time frame: Up to approximately 5 months
Volume of distribution of terminal phase (VZ)
Time frame: Up to approximately 5 months
Adverse events (AEs)
Time frame: Up to approximately 5 months
Serious adverse events (SAEs)
Time frame: Up to approximately 5 months
AEs reported as related to BMS-986446
Time frame: Up to approximately 5 months
Incidence of anti-drug antibody (ADA)
Time frame: Up to approximately 5 months
Local tolerance evaluation
This evaluation will assess pain, itching, burning, pressure, and soreness/tenderness (using a Numeric Rating Scale) at the injection site location.
Time frame: Up to approximately 5 months
GMR of Panel B1 vs Panel A3 for Cmax
Time frame: Up to approximately 5 months
GMR of Panel B1 vs Panel A3 for area under the concentration-time curve (AUC)
Time frame: Up to approximately 5 months
GMR of Panel B2 vs Panel A3 for Cmax
Time frame: Up to approximately 5 months
GMR of Panel B2 vs Panel A3 for AUC
Time frame: Up to approximately 5 months
Cmax
Panel B1, Panel B2, Panel C1
Time frame: Up to approximately 5 months
Tmax
Panel B1, Panel B2, Panel C1
Time frame: Up to approximately 5 months
AUC(0-T)
Panel B1, Panel B2
Time frame: Up to approximately 5 months
AUC(0-672)
Panel B1, Panel B2
Time frame: Up to approximately 5 months
AUC(INF)
Panel B1, Panel B2
Time frame: Up to approximately 5 months
T-HALF
Panel B1, Panel B2, Panel C1
Time frame: Up to approximately 5 months
CLT/F
Panel B1, Panel B2, Panel C1
Time frame: Up to approximately 5 months
Vz/F
Panel B1, Panel B2, Panel C1
Time frame: Up to approximately 5 months
Trough observed plasma concentration (Ctrough)
Panel C1
Time frame: Up to approximately 5 months
Concentration at the end of a dosing interval (Ctau)
Panel C1
Time frame: Up to approximately 5 months
Area under the concentration-time curve within a dosing interval (AUC(TAU))
Panel C1
Time frame: Up to approximately 5 months
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 9 months is below that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moponetug